RESULTS	Median percent reduction in seizure frequency per 28 days from baseline to maintenance period ( intent-to-treat , ITT ) was 20.5 % for placebo , 35.3 % for lacosamide 200 mg/day ( p = 0.02 ) , and 36.4 % for 400 mg/day ( p = 0.03 ) .\